3-(4-chlorophenyl)-2-(4-diethylaminoethoxyphenyl)-A-pentenonitrile monohydrogen citrate and related analogs. Reversible, competitive, first half-reaction squalene synthetase inhibitors

Biochemical Pharmacology

Volumn 53, Issue 6, 1997, Pages 839-864

  Harwood Jr , H James ^a   Barbacci Tobin, Elsa G ^a   Petras, Stephen F ^a   Lindsey, Saralyn ^a   Pellarin, Lorraine D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

cholesterol synthesis; diethylaminoethoxystilbenes; enzyme inhibition; enzyme kinetics; squalene synthetase; structure activity relationships

Indexed keywords

3 (4 CHLOROPHENYL) 2 (4 DIETHYLAMINOETHOXYPHENYL) 2 PENTENONITRILE; KETOCONAZOLE; P 3622; SQUALENE SYNTHASE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CELL CULTURE; CELL LINE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME INHIBITION; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; CRICETINAE; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; LIVER; MALE; MESOCRICETUS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0343416877     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00892-1     Document Type: Article

References (84)

1. Poulter CD, Biosynthesis of non-head-to-tail terpenes. Formation of 1'-1 and 1'-3 linkages. Acc Chem Res 23: 70-77, 1990.
2. Rilling HC, The mechanism of the condensation reactions of cholesterol biosynthesis. Biochem Soc Trans 13: 997-1003, 1985.
3. Poulter CD and Rilling HC, Conversion of farnesyl pyrophosphate to squalene. In: Biosynthesis of Isoprenoid Compounds (Eds. Porter JW and Spurgeon SL), Vol. I, Chap. 8, pp. 413-441. John Wiley, New York, 1981.
4. Popjak G and Agnew WS, Squalene synthetase. Mol Cell Biochem 27: 97-116, 1979.
5. Robinson GW, Tsay YH, Kienzle BK, Smith-Monroy CA and Bishop RW, Conservation between human and fungal squalene synthetases: Similarities in structure, function, and regulation. Mol Cell Biol 13: 2706-2717, 1993.
6. Dewar MJS and Ruiz JM, Mechanism of the biosynthesis of squalene from farnesyl pyrophosphate. Tetrahedron 43: 2661-2674, 1987.
7. Oehlschlager AC, Singh SM and Sharms S, Squalene synthetase inhibitors: Synthesis of sulfonium ion mimics of the carbocationic intermediates. J Org Chem 56: 3856-3861, 1991.
8. Capson TL, Thompson MD, Dixit VM, Gaughan RG and Poulter CD, Synthesis of ammonium analogs of carbocationic intermediates in the conversion of presqualene diphosphate to squalene. J Org Chem 53: 5903-5908, 1988.
9. Sandifer RM, Thompson MD, Gaughan RG and Poulter CD, Squalene synthetase. Inhibition by an ammonium analogue of a carbocationic intermediate in the conversion of presqualene pyrophosphate to squalene. J Am Chem Soc 104: 7376-7378, 1982.
10. Prashad M, Kathawala FG and Scallen T, N-(Arylalkyl)-farnesylamines: New potent squalene synthetase inhibitors. J Med Chem 36: 1501-1504, 1993.
11. Poulter CD, Capson TL, Thompson MD and Bard RS, Squalene synthetase. Inhibition by ammonium analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene. J Am Chem Soc 111: 3734-3739, 1989.
12. Steiger A, Pyun H-J and Coates RM, Synthesis and characterization of aza analogue inhibitors of squalene and geranyl-geranyl diphosphate synthases. J Org Chem 57: 3444-3449, 1992.
13. Corey EJ and Volante RP, Application of unreactive analogs of terpenoid pyrophosphates to studies of multistep biosynthesis. Demonstration that presqualene pyrophosphate is an essential intermediate on the path to squalene. J Am Chem Soc 98: 1291-1293, 1976.
14. Mookhtiar KA, Kalinowski SS, Zhang D and Poulter CD, Yeast squalene synthase. A mechanism for addition of substrates and activation by NADPH. J Biol Chem 269: 11201-11207, 1994.
15. Agnew WS, Squalene synthetase. Methods Enzymol 110: 359-375, 1985.
16. Goldstein JL and Brown MS, Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
17. Brown MS and Goldstein JL, Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and growth. J Lipid Res 21: 505-517, 1980.
18. Panini SR, Rogers DH and Rudney H, Regulation of HMG-CoA reductase and the biosynthesis of nonsteroid prenyl derivatives. In: Regulation of HMG-CoA Reductase (Ed. Preiss B), Chap. 5, pp. 149-181. Academic Press, New York, 1985.
19. Faust JR, Goldstein JL and Brown MS, Squalene synthetase activity in human fibroblasts: Regulation via the LDL receptor. Proc Natl Acad Sci USA 76: 5018-5022, 1979.
20. Bruenger E and Rilling HC, Prenyl transferase and squalene synthetase in livers of neonate rats. Biochim Biophys Acta 876: 500-506, 1986.
21. Keller RK, The mechanism and regulation of dolichol phosphate biosynthesis in rat liver. J Biol Chem 261: 12053-12059, 1987.
22. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA and Nelson JA, The dual role of mevalonate in the cell cycle. J Biol Chem 258: 378-385, 1983.
23. Maltese WA, Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328, 1990.
24. Ortiz deMontellano PR, Wei JS, Vinson WA, Castillo R and Boparai AS, Substrate selectivity of squalene synthetase. Biochemistry 16: 2680-2685, 1977.
25. Koyama T, Ogura K and Seto S, Substrate specificity of squalene synthetase. Biochim Biophys Acta 617: 218-224, 1980.
26. Washburn WN and Kow R, Investigations of substrate specificity of squalene synthetase. Tetrahedron Lett 18: 1555-1558, 1977.
27. Ortiz deMontellano PR, Wei JS, Castillo R, Hsu CK and Boparai AS, Inhibition of squalene synthetase by farnesyl pyrophosphate analogs. J Med Chem 20: 243-249, 1977.
28. Biller SA, Forster C, Gordon EM, Harrity T, Rich LC, Marretta J and Ciosek CP Jr, Isoprenylphosphinylformates: New inhibitors of squalene synthetase. J Med Chem 34: 1912-1914, 1991.
29. Biller SA, Forster C, Gordon EM, Harrity T, Scott WA and Ciosek CP Jr, Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase. J Med Chem 31: 1869-1871, 1988.
30. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE and Perrone MH, Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 1657-1663, 1992.
31. Prashad M, Tomesch JC, Wareing JR and Scallen T, Phosphinato(dialkylmethyl)-phosphonates as pyrophosphate mimics: Synthesis and squalene synthetase inhibitory activity of farnesyl phosphinato(dialkylmethyl)phosphonates. Eur J Med Chem 28: 527-531, 1993.
32. Biller SA, Sofia MJ, DeLange B, Forster C, Gordon EM, Harrity T, Rich LC and Ciosek CP Jr, The first potent inhibitor of squalene synthase: A profound contribution of an ether oxygen to inhibitor-enzyme interaction. J Am Chem Soc 113: 8522-8524, 1991.
33. Ciosek CP Jr, Magnin DR, Harrity TW, Logan JVH, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, Mookhtiar KA, Rich LC, Slusarchyk DA, Sulsky RB and Biller SA, Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268: 24832-24837, 1993.
34. Cohen LH, Valentijn ARPM, Roodenberg L, Van Leeuwen REW, Huisman RH, Lutz RJ, Van der Marel GA and Van Boom JH, Different analogs of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents. Biochem Pharmacol 49: 839-845, 1995.
35. Prashad M, Amidinium cation as a mimic of allylic carbocation: Synthesis and squalene synthetase inhibitory activity of an amidinium analog of a carbocation intermediate. J Med Chem 36: 631-632, 1993.
36. Magnin DR, Biller SA, Dickson JK Jr, Logan JV, Lawrence RM, Chen Y, Sulsky RB, Ciosek CP Jr, Harrity TW, Jolibois KG, Kunselman LK, Rich LC and Slusarchyk DA, 1,1-Bisphosphonate squalene synthase inhibitors: Interplay between the isoprene subunit and the diphosphate surrogate. J Med Chem 38: 2596-2605, 1995.
37. Bergstrom JD, Dufrense C, Bills GF, Nallin-Omstead M and Byrne K, Discovery, biosynthesis and mechanism of action of the zaragozic acids: Potent inhibitors of squalene synthase. Annu Rev Microbiol 49: 607-639, 1995.
38. Dawson MJ, Farthing JE, Marshall PS, Middleton RF, O'Neill MJ, Shuttleworth A, Stylli C, Tait RM, Taylor PM, Wildman HG, Buss AD, Langley D and Hayes MV, The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma. J Antibiot (Tokyo) 45: 639-647, 1992.
39. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, Sapra M, Snowden MA, Watson NS, Williams RJ and Wright C, Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 267: 11705-11708, 1992.
40. Hasumi K, Tachikawa K, Sakai K, Murakawa S, Yoshikawa N, Kumazawa S and Endo A, Competitive inhibition of squalene synthetase by squalestatin 1. J Antibiot (Tokyo) 46: 689-691, 1993.
41. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, VanMiddlesworth FL, Hensens OD, Liesch JM, Zink DL, Wilson KE, Onishi J, Milligan JA, Bills G, Kaplan L, Nallin Omstead M, Jenkins RG, Huang L, Meinz MS, Quinn L, Burg RW, Kong YL, Mochales S, Mojena M, Martin I, Pelaez F, Diez MT and Alberts AW, Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 90: 80-84, 1993.
42. Lindsey S and Harwood HJ Jr, Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation. J Biol Chem 270: 9083-9096, 1995.
43. Procopiou PA, Bailey EJ, Bamford MJ, Craven AP, Dymock BW, Houston JG, Hutson JL, Kirk BE, McCarthy AD, Sareen M, Scicinski JJ, Sharratt PJ, Snowden MA, Watson NS and Williams RJ, The squalestatins: Novel inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C1-modified analogs. J Med Chem 37: 3274-3281, 1994.
44. Bamford MJ, Chan C, Craven AP, Dymock BW, Green D, Henson RA, Kirk BE, Lester MG, Procopiou PA, Snowden MA, Spooner SJ, Srikantha ARP, Watson NS and Widdowson JA, The squalestatins: Synthesis and biological activity of some C3-modified analogues; replacement of a carboxylic acid or methyl estet with an isoelectronic heterocyclic functionality. J Med Chem 38: 3502-3513, 1995.
45. Biftu T, Acton JJ, Berger GD, Bergstrom JD, Dufresne C, Kurtz MM, Marquis RW, Parsons WH, Rew DR and Wilson KE, Selective protection and relative importance of the carboxylic acid groups of zaragozic acid A for squalene synthase inhibition. J Med Chem 37: 421-424, 1994.
46. Ponpipom MM, Girotra NN, Bugianesi RL, Roberts CD, Berger GD, Burk RM, Marquis RW, Parsons WH, Bartizal KF, Bergstrom JD, Kurtz MM, Onishi JC and Rew DJ, Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem 37: 4031-4051, 1994.
47. Chan C, Andreotti D, Cox B, Dymock BW, Hutson JL, Keeling SE, McCarthy AD, Procopiou PA, Ross BC, Sareen M, Scicnski JJ, Sharratt PJ, Snowden MA and Watson NS, The squalestatins: Decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors, J Med Chem 39: 207-216, 1996.
48. Procopiou PA, Cox B, Kirk BE, Lester MG, McCarthy AD, Sareen M, Sharratt PJ, Snowden MA, Spooner SJ, Watson NS and Widdowson J, The squalestatins: Inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues. J Med Chem 39: 1413-1422, 1996.
49. Dabrah TT, Harwood HJ Jr, Huang LH and Kaneko T, Inhibitors of squalene synthase. US5430055, 1995.
50. Dabrah TT, Harwood HJ Jr, Huang LH, Jankovich ND, Kaneko T, Li JC, Lindsey S, Moshier PM, Subashi TA, Therrien M and Watts PC, CP-225917 and CP-263114, novel bioactive compounds from an unidentified fungus. I. Taxonomy, fermentation, isolation, and biochemical properties. J Antibiot (Tokyo), in press.
51. Dabrah TT, Kaneko T, Massesfki WW Jr and Whipple EB, CP-225917 and CP-263114, novel bioactive compounds from an unidentified fungus. II. Structural elucidations. J Am Chem Soc, in press.
52. (a) Meinz MS, Palaez F, Nallin-Omstead M, Milligan JA, Diez MT, Onishi JC, Bergstrom JD, Jenkins RF, Harris GH, Jones ETT, Huang L, Kong YL, Lingham RB and Zink D, EP 526936A, 1993;
53. (b) Harris GH, Joshua H and Zink D, US 5286895, 1994;
54. (c) Tsujita Y, Hamano K, Fulioka T, et al., JP 7041454, 1995.
55. (a) Yukimasa H, Tozawa R, Kori M and Kitano K, EP 567026 A1, 1993;
56. (b) Nomoto T, Masahiro H, Shibata J, Iwasawa Y, Mitsuya M, Lida Y, Nonoshita K and Nagata Y, EP 611749 A, 1994;
57. (c) Baker WR, Rockway TW, Donner B, Shen W, Rosenberg SH, Fakhoury SA, O'Connor SL, Stout DM, Fung AK, Garvey DS, Prasad R and Sullivan GM, WO9512572, 1995.
58. Brown GR, Butlin RJ, Chapman S, Eakin MA, Foubister AJ, Freeman S, Griffiths D, Harrison PJ, Johnson MC, Mallion KB, McTaggart F, Reid AC, Smith GJ, Taylor MJ, Walker RP and Wittamore PRO, Phenoxypropylamines: A new series of squalene synthase inhibitors. J Med Chem 38: 4157-4160, 1995.
59. (a) Brown GR, Mallion KB and Harrison PJ, WO 9313096, 1993; WO 9309115, 1993;
60. (b) Alberts AW, Berger GD and Bergstrom JD, US5135935, 1992;
61. (c) Neuenschwander K, Amin D, Scotese AC and Morris RL, WO 9215579, 1992.
62. Biller SA, Abt JW, Pudzianowski AT, Rich LC, Slusarchyk DA and Ciosek CP Jr, Aromatic isosteres as conformational probes for an isoprenyl subunit: Application to inhibitors of squalene synthase. Bioorg Med Chem Lett 3: 595-600, 1993.
63. Hughes GMK, Moore PF and Stebbins RB, Some hypocholesterolemic 2,3-diphenylacrylonitriles. J Med Chem 7: 511-518, 1964.
64. Figdor SK, Schreiber EC, Stebbins RB, Moore PF and Pinson R Jr, A correlation of drug concentration with sterol biosynthesis inhibition in the liver. J Med Chem 7: 508-510, 1964.
65. Harwood HJ Jr, Greene YJ and Stacpoole PW, Inhibition of human leukocyte HMG-CoA reductase activity by ascorbic acid, an effect mediated by the free radical monodehydroascorbate. J Biol Chem 261: 7127-7135, 1986.
66. Harwood HJ Jr, Protein farnesyltransferase: Measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology. Anal Biochem 226: 268-278, 1995.
67. Harwood HJ Jr, Silva M, Chandler CE, Mikolay L, Pellarin LD, Barbacci-Tobin E, Wint LT and McCarthy PA, Efficacy, tissue distribution and biliary excretion of methyl(3R*,5S*)-(E)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoate (CP-83101), a hepatoselective inhibitor of HMG-CoA reductase activity in the rat. Biochem Pharmacol 40: 1281-1293, 1990.
68. Holmes WL and DiTullio NW, Inhibitors of cholesterol biosynthesis which act at or beyond the mevalonic acid stage. J Clin Nutr 10: 310-321, 1962.
69. Clarke S, Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61: 355-386, 1992.
70. Hancock JF and Marshall CJ, Posttranslational processing of ras and ras-related proteins. In: The ras Superfamily of GTPases (Eds. Lacal JC and McCormick F), Chap. 3, pp. 65-84. CRC Press, Ann Arbor, MI, 1992.
71. Poulter CD and Rilling HC, Prenyl transferases and isomerase. In: Biosynthesis of Isoprenoid Compounds (Eds. Porter JW and Spurgeon SL), Vol. I, Chap. 4, pp. 162-224. John Wiley, New York, 1981.
72. Beytia ED and Porter JW, Biochemistry of polyisoprenoid synthesis. Annu Rev Biochem 45: 113-142, 1976.
73. Pennock JF and Threlfall DR, Biosynthesis of ubiquinone and related compounds. In: Biosynthesis of Isoprenoid Compounds (Eds. Porter JW and Spurgeon SL), Vol. II, Chap. 4, pp. 191-303. John Wiley, New York, 1983.
74. Hemming FW, Biosynthesis of dolichols and related compounds. In: Biosynthesis of Isoprenoid Compounds (Eds. Porter JW and Spurgeon SL), Vol. II, Chap. 5, pp. 305-354. John Wiley, New York, 1983.
75. Furfine ES, Leban JJ, Landavazo A, Moomaw JF and Casey PJ, Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 34: 6857-6862, 1995.
76. Rotstein DM, Kertesz DJ, Walker KAM and Swinney DC, Sterioisomers of ketoconazole: Preparation and biological activity. J Med Chem 35: 2818-2825, 1992.
77. Rilling HC and Chayet LT, Biosynthesis of cholesterol. In: Sterols and Bile Acids (Eds. Danielsson H and Sjovall J), Chap. 1, pp. 1-39. Elsevier, New York, 1985.
78. Black ML, Rodney G and Capps DB, Simultaneous inhibition of alternative pathways of cholesterol biosynthesis by two related hypocholesteremic agents. Biochem Pharmacol 17: 1803-1814, 1968.
79. Gylling H, Mantyla E and Miettinen TA, Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis. Atherosclerosis 96: 245-247, 1992.
80. Teo CC, Kon OL, Sim KY and Ng SC, Synthesis of 2-(pchlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. J Med Chem 35: 1330-1339, 1992.
81. Harrity TW, George RJ, Ciosek CP Jr, Biller SA, Chen Y, Dickson JK, Fryszman OM, Jolibois KJ, Kunselman LK, Lawrence RM, Logan JVH, Magnin DR, Rich LC, Slusarchyk DA, Sulsky RB and Gregg RE, BMS-188494, an orally active squalene synthase inhibitor which lowers cholesterol in animals. In: XII International Symposium on Drugs Affecting Lipid Metabolism, Book of Abstracts, p. 54. Elsevier, Amsterdam, 1995.
82. Petras SF and Harwood HJ Jr, Reversible, competitive, squalene synthetase first half-reaction inhibitors do not induce compensatory increases in HMG-CoA reductase activity. FASEB J 9: A1282, 1995.
83. Ness GC, Eales S, Lopez D and Zhao Z, Regulation of HMG-CoA reductase gene expression by sterols and nonsterols in rat liver. Arch Biochem Biophys 308: 420-425, 1994.
84. Straka MS and Panini SR, Post-transcriptional regulation of HMG-CoA reductase by mevalonate. Arch Biochem Biophys 317: 235-243, 1995.